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Abstract: The effectiveness and safety of shoulder arthroplasties in the general context of a Spanish
patient population remains unclear. The aim of this study was to ascertain both the effectiveness and
safety of primary shoulder arthroplasties and the prosthesis types used in Spain. A systematic review
of all the available literature evaluating the effectiveness and safety of primary shoulder arthroplasties
in Spain was performed. A narrative synthesis was performed, and evidence tables were created in
four dimensions: study design, arthroplasty characteristics, safety, and effectiveness. Orthopaedic
Data Evaluation Panel (ODEP) scores were used to evaluate prosthesis types. Twenty-one studies were
selected that included a total of 1293 arthroplasties. The most common indication was fractures, while
the prosthesis most frequently used was the Delta Xtend (ODEP 10A). The most common complication
was scapular notching. Prosthesis revision rate was approximately 6% for follow-ups between 12 and
79 months. In addition, significant improvements were observed in the Constant–Murley test score
after the intervention. Currently in Spain, shoulder arthroplasty can be considered a safe and effective
procedure with functional recovery and pain reduction for eligible patients with humeral fracture,
rotator cuff arthropathy, fracture sequelae and malunion of the proximal humerus, and degenerative
disease. Future longitudinal research and population-based studies could serve to confirm these
results and identify points of improvement.
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1. Introduction
Shoulder arthroplasty is currently considered to be an established therapeutic option and an
effective and efficient procedure to improve physical function, pain and quality of life in patients [1–5].
As a result of continual technological progress and emerging indications for shoulder arthroplasty,
including proximal humeral fractures, osteoarthritis and massive rotator cuff tears [6], the utilization
of this procedure has increased throughout the world and in some countries it has tripled in the last
decade [7–9].
The use of shoulder arthroplasty has increased significantly in Spain in recent years [10,11], but
remains a lower-volume procedure compared to knee and hip replacement. Given the increasing
indication for these types of procedures and their potential to improve the health of patients, it is vitally
important for both patients and clinicians that the complications associated with these interventions
are well understood. Previous research has proposed that the three most common complications are
instability, periprosthetic fracture and infection [12–14]. Understanding this information within the
context of the effectiveness of different types of prostheses and models, and in certain population
groups, is likely to be highly relevant [1,7,14]. However, as far as we know, no studies have evaluated
the effectiveness and safety of these procedures in the general context of a Spanish population.
Furthermore, there is no arthroplasty register that can be directly assessed. Both analysing the results
of these procedures by population and establishing a registry could be useful in evaluating the results
of shoulder arthroplasties more precisely in a specific healthcare context such as Spain, facilitating a
comparison to other international contexts.
Regarding the safety and effectiveness of primary shoulder arthroplasties, evidence suggests
that some of the most frequent complications associated with this procedure are scapular notching,
dislocation, periprosthetic fracture, and infection [14–16]. Furthermore, the revision rate of shoulder
arthroplasties is estimated to be approximately 5% and 10% at 5 and 10 years respectively, and may be
lower in reverse arthroplasties compared to hemiarthroplasty and total shoulder arthroplasty [15–17].
However, in the Spanish context, to date no population-level studies have been conducted to evaluate
these outcomes, or aimed to quantify the safety and effectiveness of primary shoulder arthroplasties.
Furthermore, the evidence found in specific studies that have already been carried out is divergent,
which may be due to a focus on specific models or types of prostheses, or certain pathologies and
clinical populations [18–20].
In this context, the objective of this study was to describe the scientific evidence available on the
effectiveness and safety of primary shoulder arthroplasties in Spain and the types of prosthesis used in
this population.
2. Materials and Methods
A systematic review was conducted on the results of shoulder arthroplasties performed in
public hospitals in Spain, and the results are reported according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) criteria [21]. The review has been registered
in PROSPERO (CRD42019115342). The following databases were used as sources of information:
EMBASE, PubMed, Scielo, Cochrane Reviews and Center for Reviews and Dissemination. The search
range was restricted from January 2003 to December 2018. Given the continuous improvement in
shoulder arthroplasty results and the advancement in surgical techniques, the lower limit was set
at 2003. This limit was fixed in order to maximize the study period and overcome any potential
limitations related to underestimating the current results after pooling long-term retrospective data.
A search filter was developed specifically designed for PubMed/Medline to achieve the objectives
of this study (Appendix A), and was adapted to other databases. The search strategy was based on
previous studies in an attempt to maximize the number of documents identified [22–24]. Keywords for
procedure as well as anatomical and territorial location were used. In addition, the references found in
systematic reviews and meta-analyses were used to identify primary studies, a grey literature search
was conducted, and key authors were contacted.
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2.1. Inclusion and Exclusion Criteria and the Revision Process
The PICO criteria (population, intervention, comparison, outcome) were used to identify studies.
We included documents in English and Spanish that focused on the evaluation of effectiveness and
safety in primary shoulder arthroplasties performed in public hospitals in Spain. Due to limitations
related to the robustness of the data and possible biases when making inferences in the population,
only studies with a sample size of 20 or more primary interventions were included. Documents that
included patients under 18 years of age, studies that evaluated revision implants or those indicated for
tumours or congenital diseases, and studies aimed at evaluating surgical techniques were excluded.
Additionally, studies evaluating complications, adverse effects and/or effectiveness based on certain
patient characteristics were excluded due to the difficulty in generalizing and comparing their results.
A screening of the title, summary and full text was carried out independently by two expert
reviewers (JAT and XGC), while possible discrepancies were resolved by a third reviewer (KS). After
study selection, a narrative synthesis of the evidence obtained was carried out. Given the variability
in study characteristics and outcome variable presentation, a meta-analysis was deemed unfeasible.
Therefore, the information was extracted in various tables of evidence with four dimensions: study
design, arthroplasty characteristics, safety and effectiveness of primary shoulder arthroplasties. To
evaluate the prosthesis models, the Orthopaedic Data Evaluation Panel (ODEP) scores were used [25].
ODEP is a panel of independent experts that publishes reference indexes to assess the effectiveness
of different models of anatomical and reverse prostheses. The criteria used were based on implant
survival, follow-up time and the size of the cohort analysed. Based on these criteria, implants were
assigned to categories in terms of the evidence supporting their use.
2.2. Quality of Studies Included
The quality of the studies and their design were considered according to the Scottish Intercollegiate
Guidelines Network (SIGN) levels of evidence hierarchy [26]. Furthermore, the Risk of Bias tool
(RoB 2.0) was used for randomized trials to assess the quality of evidence [27], while for non-randomized
trials, the Risk of Bias in Non-Randomized Studies of Interventions tool (ROBINS-I) was used [28].
Finally, for single-cohort study designs, the scale of evidence assessment for case series studies from
the Institute of Health Economics was used [29].
SIGN levels were assigned according to the quality of the study evidence based on their design
from the 1 ++ level of higher evidence reserved for high-quality meta-analyses, systematic reviews of
randomized clinical trials, and randomized clinical trials with very low risk of bias, to level 4, which
includes expert opinion. To compare studies, the risk of bias for each reference was calculated using
the RoB 2.0 and ROBINS-I tools [27,28], assigning 4 points to “critical” risk assessments; 3 points to
“high” risk; 2 points to “moderate” risk, “some considerations” or cases assessed with “insufficient
information”; and 1 point for “low” risk assessment. Next, the percentage of points obtained over
the total points possible for all categories was calculated. For single-cohort studies, the percentage of
positive responses was obtained from the assessment scale.
3. Results
A total of 360 references were identified (259 from EMBASE, 84 from PubMed and 17 from SCIELO)
(Figure 1). After eliminating duplicates, 323 were screened by title and abstract. After screening,
277 documents were excluded, thus including 46 for full-text review. Of these 46 references, 25 were
excluded and 21 studies were included in the final evidence tables [18–20,30–47].
Table 1 shows the level of evidence of the selected studies. Two randomized clinical trials had
a SIGN 1+ level and two non-randomized clinical trials a SIGN 2 ++. The remaining studies were
observational, 11 of which were retrospective. In terms of risk of bias assessment, little variability was
observed in the risk attributed to the different studies. The greatest risk of bias came from subjectivity in
measuring outcome variables, followed by the possible impact of uncontrolled confounding variables.
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The average range for patient follow-up was between 12 and 79 months, and included the results of
1293 arthroplasties. The number of cases per study ranged from 21 to 163.
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Table 1. Primary shoulder arthroplasties. Evidence, risk of bias, and study design. 
Author, Year 
SIGN Level  
of Evidence 
Risk of 
Bias (%) 
Study Type  
(Time Period) 
Average Patient Follow-
up in Months  
Total Number 
of Cases 
Torrens et al.,  
2016 
1+ 56 
Randomized controlled 
trial (2010–2012) 
24 81 
Sebastià Forcada et al.,  
2014 
1+ 56 
Randomized controlled 
trial (2009–2011) 
30 reverse and 28 partial 61 
Boyer et al.,  
2017 
2++ 39 Nonrandomized trial 
(2009–2011) 
15 reverse and 25 partial 134 
Alentorn-Geli et al.,  
2014 
2++ 50 Nonrandomized trial 
(2005–2012). 
40 reverse and 72 partial 32 
Jorge-Mora et al.,  
2018 
2+ 43 Retrospective 
observational (2012–2017) 
26 114 
Sebastià Forcada et al.  
2017 2+ 54 
Retrospective 
observational (2009–2011) 
40 plate failure and 37 
acute fracture 60 
Lopiz et al.,  
2016 2+ 54 
Retrospective 
observational (2009–2012) 33 42 
Bonilla et al.,  
2012 
2- 54 
Retrospective 
observational (2003–2011) 
25 Delta and 9 
Comprehensive 
43 
Izquierdo-Fernández et al.,  
2017 
2- 46 
Prospective observational 
(2012) 
48 29 
Cáceres-Sánchez et al.,  
2015 
3 50 
Retrospective 
observational (2004–2012) 
36 52 
Martinez et al.,  
2012 
3 43 Prospective observational 
(2003–2007) 
48 44 
Zafra et al.,  
2014 
3 43 Prospective observational 
(2003–2011) 
51 35 
García-Fernandez et al.,  
2015 3 39 
Retrospective 
observational (2003–2014) 79 163 
Figure 1. Study selection flow diagram.
Table 2 shows that the average age of patients included was over 70 years, approximately 70%
of whom were omen. In addition, two studies documented low comorbidity i thei patients
(Charlson Comorbidity Index less than 2) [18,19]. There were four main indications for un ertaking
primary arthroplasty: acute fractures and fracture-dislocation of the proximal humerus, rotator cuff
arthr pathy, fractur sequelae and malunion o the proximal humerus, and degener tive diseases.
About half of the interve tions were perform d using a deltopectoral approach, while the rest used a
superolateral or anterosup rior appro ch. In terms of implant characteristics and fixation, 18 studies
i l reve se prostheses, 8 of which u ed a cemented fix tion and 6 of which were non-cemented.
The most frequently used prosthesis models included in these studies were the Delta Xtend, with an
ODEP assessment of 10A, and the Delta III, which is not evaluated by ODEP. The third most frequent
was the Lima SMR, with an ODEP rating f 10A.
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Table 1. Primary shoulder arthroplasties. Evidence, risk of bias, and study design.
Author, Year SIGN Level ofEvidence Risk of Bias (%) Study Type (Time Period)
Average Patient
Follow-Up in Months
Total Number
of Cases
Torrens et al., 2016 1+ 56 Randomized controlled trial (2010–2012) 24 81
Sebastià Forcada et al., 2014 1+ 56 Randomized controlled trial (2009–2011) 30 reverse and 28 partial 61
Boyer et al., 2017 2++ 39 Nonrandomized trial (2009–2011) 15 reverse and 25 partial 134
Alentorn-Geli et al., 2014 2++ 50 Nonrandomized trial (2005–2012). 40 reverse and 72 partial 32
Jorge-Mora et al., 2018 2+ 43 Retrospective observational (2012–2017) 26 114
Sebastià Forcada et al. 2017 2+ 54 Retrospective observational (2009–2011) 40 plate failure and 37acute fracture 60
Lopiz et al., 2016 2+ 54 Retrospective observational (2009–2012) 33 42
Bonilla et al., 2012 2- 54 Retrospective observational (2003–2011) 25 Delta and 9Comprehensive 43
Izquierdo-Fernández et al., 2017 2- 46 Prospective observational (2012) 48 29
Cáceres-Sánchez et al., 2015 3 50 Retrospective observational (2004–2012) 36 52
Martinez et al., 2012 3 43 Prospective observational (2003–2007) 48 44
Zafra et al., 2014 3 43 Prospective observational (2003–2011) 51 35
García-Fernandez et al., 2015 3 39 Retrospective observational (2003–2014) 79 163
Alcobía-Díaz et al., 2017 3 43 Retrospective observational (2009–2011) 53 116
Torrens et al., 2016 3 43 Prospective observational (NS) 12 60
Torrens et al., 2017 3 36 Prospective observational (NS) 24 58
Torrens et al., 2018 3 36 Retrospective observational (2010–2012) 29 41
Delgado-Rodríguez et al., 2013 3 54 Retrospective observational (2006–2010) 17 40
Hernández-Elena et al., 2015 3 43 Retrospective observational (2009–2013) 18 37
Villodre-Jiménez et al., 2016 3 43 Prospective observational (2008–2014) 34 30
Andrés-Cano et al., 2014 3 43 Retrospective observational (2009–2010) 21 21
SIGN: Scottish Intercollegiate Guidelines Network; NS: Not specified.
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Table 2. Characteristics of shoulder arthroplasties included in the selected studies.
Author, Year Diagnosis Patient Characteristics Characteristics of the Intervention Arthroplasty andFixation ODEP Model Rating
Torrens et al., 2016
Rotator cuff arthropathy (82%
G38 vs. 63% G42), Proximal
humeral fracture (18% G38 vs.
26% G42) and fracture sequelae
(13% G38 vs. 11% G42).
Average age, 75 years G38 (88%
women) vs. 76 G42 (84% women).
Glenoid component fixed without
retroversion, metaglene, flush. Deltopectoral
approach for sequelae fractures and anterior
superior in acute fractures, and pretension of
the rotator cuff. Movement starting at 24 h,
Sling: 3 weeks.
Reverse.
Delta Xtend - 10A; glenoid
component size
(38 vs. 42 mm).
Sebastià Forcada et al.,
2014
Proximal humeral fracture in
three (16% reverse vs. 13%
partial) and four fragmented
(84% reverse vs. 87% partial).
Rotator cuff arthropathy: 55%
reverse vs. 63% partial.
Average age: 75 years, reverse
(87% women, 61% lesion in dominant
arm) vs. 73 years, partial
(83% women).
Deltopectoral approach. Sling: 3 weeks.
Average time between fracture and surgery:
5 days. Rehabilitation: beginning of active
and passive movement at 2 weeks, active
with resistance at 6 weeks.
Reverse vs. partial
(non-cemented). Lima SMR - 10A.
Boyer et al., 2017 Three- and four-part proximalhumeral fractures.
Average age: 78 years, reverse vs.
68 years partial.
Deltopectoral (88%) or superolateral (12%)
approach. Average time between fracture
and surgery: 7 days.
Reverse vs. partial.
Non-cemented
(using two screws).
-
Alentorn-Geli et al., 2014 Fracture sequelae of the proximalhumerus.
Average age: 79 years, reverse
(80% women) vs. 83 years, partial
(33% women).
Deltopectoral (84%) or superolateral (16%)
approach. Tuberosity osteotomy type IV.
Subscapularis repair in partial arthroplasties
and in the reverse deltopectoral approach.
Reverse vs. partial.
Reverse - Delta Xtend -
10A vs. Partial: Global
Advantage.
Jorge-Mora et al., 2018 Proximal humeral fracture.
Average age: 78 years, cemented
(100% women) vs. 76 years,
non-cemented (91% women)/76 years
union (95% women) vs. 78 years
non-union (95% women).
Approach: deltopectoral cemented (92%) vs.
non-cemented (94%)/deltopectoral union
(92%) vs. nonunion (95%), the rest
superolateral. Average time between
fracture and surgery: 9 days cemented/8
days union vs. 8 days nonunion.
Total reverse: cemented
vs. non-cemented.
Arrow shoulder fracture
and anatomic shoulder
reconstruction vs.
Humelock II.
Sebastià Forcada et al.,
2017
Complex fracture sequela due to
fixation failure of proximal
humeral plate vs. proximal
humeral fracture.
Average age: 73 years, sequela
(63% women, 43% dominant arm) vs.
75 years, fracture (63% women).
Deltopectoral approach. Average of
2.311 days between fracture and intervention
in the group with sequelae. Sling: 3 weeks.
Rehabilitation: started at 3 weeks, lasted
4 weeks.
Total reverse,
non-cemented. Lima SMR - 10A.
Lopiz et al., 2016
Humerus fracture: three (12% vs.
19%) and four (42% vs. 48%)
fragmented and dislocated
fractures (46% vs. 37.5%).
Over 80 years old vs. under 80 years
old. 80% women. Dominant
shoulder inured (62%).
Deltopectoral approach. Average of 6 days
between fracture and intervention.
Rehabilitation: passive movement from 24 h
post intervention to 2 weeks, exercises for
3–4 weeks.
Reverse cemented. Delta Xtend - 10A.
Bonilla et al., 2012
Rotator cuff arthropathy or
osteoarthritis secondary to rotator
cuff tear.
Average age: 76 years, Delta vs.
(87.5% women, 81% right arm) vs.
72 years Comprehensive
(92% women)
Approach: Delta Xtend transdeltoid vs.
Comprehensive deltopectoral. Reverse.
Delta Xtend - 10A vs.
Comprehensive Reverse
Shoulder System - 5A.
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Table 2. Cont.
Author, Year Diagnosis Patient Characteristics Characteristics of the Intervention Arthroplasty andFixation ODEP Model Rating
Izquierdo-Fernández
et al., 2017
Rotator cuff arthropathy,
fractures, or dislocations.
Average age: 78 years (80% women).
Body mass index ≤35 vs. >35. - Reverse. Delta Xtend - 10A.
Cáceres-Sánchez et al.,
2015
Proximal humeral fracture (10%),
prosthetic revision (12%), fracture
sequelae (19%), rotator cuff tear
(60%).
Average age: 70 years (84% women).
Deltopectoral approach. Sling: 3 weeks.
Rehabilitation: passive movements between
the 1st and 3rd weeks, active movements
between the 2nd and 4th weeks and muscle
enhancement between the 3rd and
12th weeks.
Reverse.
Delta Xtend - 10A (58%)
and Aequalis Reversed -
5A (42%).
Martinez et al., 2012 Fracture sequelae of the proximalhumerus. Average age: 77 years (60% women).
Deltopectoral approach: Average time
between fracture and surgery: 365 days.
Rehabilitation: starting at 3 weeks.
Reverse cemented (45%)
or non-cemented (55%). Lima SMR - 10A.
Zafra et al., 2014
Error in the treatment of proximal
humeral fractures in two (40%),
three (26%), and four parts (34%).
Average age: 69 years. Fracture in
dominant arm (86%). Deltopectoral approach. Reverse cemented. Delta III.
García-Fernandez et al.,
2015
Rotator cuff injury (30%), rotator
cuff arthropathy (44%), proximal
humeral fractures (26%).
Average age: 76 years (87.5% women)
for the sample that included
40 additional revision arthroplasties.
Approach: deltopectoral (fractures) or
superolateral (rotator cuff tears and
arthropathies)
Reverse (cemented and
non-cemented).
Delta III (9%), Delta Xtend
(43%) - 10A, Lima SMR
(29%).
Alcobía-Díaz et al., 2017 Rotator cuff arthropathy.
Average age: 81 years (88% women)
Charlson Comorbidity Index:
1.7 = low comorbidity.
Superolateral approach (76%) or
deltopectoral (24%). Passive rehabilitation
during hospital stay, exercises for 6 weeks.
Total. -
Torrens et al., 2016 Rotator cuff arthropathy. Average age: 74.5 years(92% women). Reverse. Delta Xtend - 10A.
Torrens et al., 2017
Reverse (71%): 43% rotator cuff
arthropathy, 28% proximal
humeral fractures. Total: 22%
primary osteoarthritis. Partial:
7% proximal humeral fractures.
Average age: fractures, 74 years;
osteoarthritis, 78 years; arthropathy,
74 years (88% women).
Reverse: anterosuperior approach.
Anatomic: deltopectoral approach. Average
time between fracture and surgery: 11 days.
Total anatomic (23%),
partial (7%) and reverse
(70%).
Reverse: Delta Xtend - 7A,
Total: Global AP - 5A,
Partial: Global Unite.
Torrens et al., 2018 Proximal humeral fracture inthree (17%) or four parts (83%).
Average age: 78 years
(87.5% women). Average BMI: 28.
Anterosuperior approach. Average time
between fracture and surgery: 12 days. Reverse cemented. Delta Xtend - 10A.
Delgado-Rodríguez et al.,
2013 Proximal humeral fracture.
Average age: 76 years
(87.5% women).
Rehabilitation: average start at 4 weeks.
Average number of sessions = 39. Partial.
Hernández-Elena et al.,
2015
Proximal humeral fracture with
risk of osteonecrosis of the
humeral head. Type of fracture:
four fragments (54%), three
fragments (30%),
fracture-dislocation (16%).
Average age: 77 years (97% women).
Deltopectoral approach. Rehabilitation:
starting at 2 weeks with passive movement,
resistance exercises starting at 6 weeks.
Reverse. Aequalis
® Reversed II -
5A.
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Table 2. Cont.
Author, Year Diagnosis Patient Characteristics Characteristics of the Intervention Arthroplasty andFixation ODEP Model Rating
Villodre-Jiménez et al.,
2016
Humerus fracture in three parts
(27%) and four parts (73%). With
non-reconstructible fractures, risk
of avascular necrosis, severe
osteoporosis and previous rotator
cuff injuries.
Average age: 75 years (87% women).
Deltopectoral approach. Sling: 3 weeks.
Rehabilitation: passive movement starting at
3 weeks, exercises starting at 6 weeks.
Reverse cemented. Lima SMR - 10A.
Andrés-Cano et al., 2014
Proximal humeral fracture in
three (10%) or four parts (57%),
fracture-dislocation (33%).
Average age: 72 years (90% women).
Charlson Comorbidity: 0 or 1.
Deltopectoral approach. Average time
between fracture and surgery: 17 days. Sling:
5 weeks. Rehabilitation starting at 4 weeks.
Partial non-cemented. Epoca ShoulderArthroplasty System.
ODEP: Orthopaedic Data Evaluation Panel; G38: 38 mm glenosphere; G42: 42 mm glenosphere; %: percentage; BMI: body mass index; -: no information available.
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Table 3 shows that the most frequent complication in reverse shoulder arthroplasties was scapular
notching, reported in 14 studies [33,48]. One study found a higher presence in older patients [46].
In terms of complications associated with tuberosities, malunion was documented in six studies,
with the maximum rate being 33%. Additionally, resorption of the tuberosities was reported in five
studies. Prosthesis infection was documented in seven of the included studies, with one study citing
up to 8% [34]. Intraoperative fractures were also documented in seven studies, with the highest
values being 7%. Similarly, periprosthetic fracture in five documents and ossification in one were
also seen. There was a 1% dislocations rate, and less than 1% were complications relating to fixation,
positioning, and movement of the prosthesis. The main neurological vascular and lymphatic system
complications were paralysis in three studies and hematoma in three others. In terms of prosthesis
survival, 67% of the studies selected cited approximately 6% revision rate between 12 and 78 months.
A significant difference was found in the revision rate in two studies comparing partial arthroplasties
(hemiarthroplasty) to reverse arthroplasties [32,34]. The revision rate for hemiarthroplasties was far
higher, with a difference greater than 15% in both studies.
In terms of the effectiveness of shoulder arthroplasties, Table 4 shows that in the studies evaluating
patients before the intervention, the Constant–Murley test score was approximately 30%. After the
intervention, the average score was approximately 65%, with significant improvement reported in four
studies [20,30,34,41]. Seven of the eight studies included metrics before and after reported improvement
in external rotation, with three studies being statistically significant. In one study, better results in
terms of hemiarthroplasties were observed in reverse prostheses [32]. Five of the seven studies that
dealt with internal rotation and analysed metrics before and after reported improvements in movement.
One of these studies had a significant difference. Better results were observed in patients that had
fractures with tuberosity union compared to a group of patients with tuberosity malunion [35]. Sixteen
of the 21 studies considered other results, highlighting their frequency on the UCLA Shoulder Rating
Scale (UCLA) in two studies, Disabilities of the Arm, Shoulder and Hand (DASH) or QuickDASH in
six studies and on Visual Analog Scale (VAS) in four studies.
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Table 3. Reliability of primary shoulder arthroplasties.
Author, Year Scapular Notching Infection Fractures, Tears andOssifications
Complications in
Tuberosities
Fixation, Dislocation or
Stiffness
Complications
Neurological, Vascular
and/or Lymphatic
Complications
Reinterventions and
Revisions
Torrens et al., 2016
Scapular neck notching
(with intention to treat)
46% G38 vs. 30% G42.
0% G38 vs. 3%
G42 - -
Dislocation: 3% G38 vs.
2% G42. -
Revision: 3% G38 vs.
2% G42.
Sebastià Forcada et al.,
2014
Scapular neck notching:
3% Reverse vs. 0%
partial.
3% reverse vs. 3%
partial.
Intraoperative fracture:
0% reverse vs. 3%
partial. Ossification:
16% reverse vs. 20%
partial
Malunion: 19% reverse
vs. 13% partial (p = 0.4).
Resorption: 16% reverse
vs. 30% partial (p = 0.4).
Rigidity: 0% reverse vs.
3% partial. Migration:
0% reverse vs. 20%
partial. Radiolucency:
13% reverse vs. 10%
partial.
Hematoma: 0% reverse
vs. 4% partial.
Revision before the
40th month: 3%
reverse vs. 20%
partial.
Boyer et al., 2017 Notching: Reverse (8%)vs. partial (0%). -
Periprosthetic fracture:
3% reverse vs. 1%
partial. Cuff tear: 0%
reverse vs. 5% partial.
Lysis 6% reverse vs. 2%
partial.
Poor fixation: 7%
reverse vs. 2% partial.
Phlebitis: 3% reverse vs.
0% partial. Paralysis: 1%
reverse vs. 1% partial.
Lymphedema: 0%
reverse vs. 2% partial.
Revision: 7% reverse
vs. 2% partial.
Alentorn-Geli et al.,
2014
Glenoid erosion: 0%
reverse vs. 8% partial.
0% reverse vs. 8%
partial. - - - -
Revision: 0% reverse
vs. 25% partial.
Jorge-Mora et al., 2018 -
Early infection: 0%
cemented vs. 3%
non-cemented.
Periprosthetic fracture:
0% cemented vs. 3%
non-cemented.
Poor reinforcement:
33%, 54% cemented vs.
76% non-cemented (p =
0.07).
Dislocation: 0%
cemented vs. 3%
non-cemented.
Paralysis: 0% cemented
vs. 3% non-cemented.
Revision: 0%
cemented vs. 9%
non-cemented.
Sebastià Forcada et al.,
2017 0%. -
Acromion fracture: 3%
sequela vs. 0% acute.
Intraoperative fracture:
0% sequelae vs. 3%
acute.
-
Dislocation: 7% sequela
vs. 0% acute. Loosening
3% sequela vs. 0% acute.
Radiolucency: 7%
sequela vs. 0% fracture.
- Revision: 13% sequelavs. 0% fracture.
Lopiz et al., 2016 Scapular notching: 14%. Periprosthetic fracture:2%.
Malunion: 19%.
Resorption: 5%.
Dislocation: 2%.
Radiolucency: 0%. Hematoma: 4%. Revision: 2%.
Bonilla et al., 2012
Scapular notching: 31%
Delta vs. 9%.
Comprehensive.
6% Delta vs. 0%
Comprehensive - -
Migration: 3% Delta vs.
0% Comprehensive. -
Revision: 9% Delta vs.
0% Comprehensive.
Izquierdo-Fernández
et al., 2017
Scapular notching: 47%
BMI < 35 vs. 50%
BMI > 35.
- - - Radiolucency: 57% vs.37.5% (p = 0.3). - -
Cáceres-Sánchez et al.,
2015 Scapular notching: 17%. 4%.
Acromion fracture: 2%.
Intraoperative fracture:
2%.
-
Radiolucency: 2%
Instability: 4%
Loosening: 4%.
- Reintervention: 9%.
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Table 3. Cont.
Author, Year Scapular Notching Infection Fractures, Tears andOssifications
Complications in
Tuberosities
Fixation, Dislocation or
Stiffness
Complications
Neurological, Vascular
and/or Lymphatic
Complications
Reinterventions and
Revisions
Martinez et al., 2012 Glenoid notching: 41%.Scapular notching: 41%. - - Resorption: 7%.
Radiolucency: 11%.
Dislocation: 14%.
Loosening: 2%.
Paralysis 1%. Revision: 11%.
Zafra et al., 2014 60%. -
Intraoperative fracture:
5%. Periprosthetic
fracture: 2%.
- Radiolucency: 65%humeral, 31.5% glenoid. -
Other complications
(20%).
García-Fernandez
et al., 2015 - -
Periprosthetic humerus
fracture: intraoperative
with non-cemented
Lima SMR (1%),
postoperative with Lima
SMR (1%).
- - - -
Alcobía-Díaz et al.,
2017 - - - - - -
10% analgesic
treatment 6 weeks
after the intervention.
Torrens et al., 2016 - - - - - - -
Torrens et al., 2017 - 0%. - - - - -
Torrens et al., 2018 Scapular notching: 15%. - Presence of osteophyte:12%.
Malunion: 32%.
Resorption: 10%. Poorer
union, depending on
comorbidity.
- Paraesthesia: 15%. Revision: 2%.
Delgado-Rodríguez
et al., 2013 - - - - - - -
Hernández-Elena
et al., 2015
Scapular notching (29%).
Relationship between
notching and age.
- Intraoperative fracture:2%. - -
Hematoma: 5%.
Neuropraxia: 3%. -
Villodre-Jiménez et al.,
2016
Scapular notching
(46%). -
Intraoperative fracture:
7%. Malunion: 33%. - -
Other complications:
46%.
Andrés-Cano et al.,
2014 - - -
Malunion: 5%.
Resorption: 24%. Radiolucency: 5%. - -
G38: 38 mm glenosphere; G42: 42 mm glenosphere; BMI: Body Mass Index; p: p-value; -: no information available.
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Table 4. Effectiveness of primary shoulder arthroplasties.
Author, Year Constant–Murley Score Joint Assessment, by Constant–Murley Score Other Results
Torrens et al., 2016
Global score: 29 before—57 after G38 vs.
26 before—55 after G42. Pain: 5
before—11 after G38 vs. 5 before—11
after G42. Daily activities: 8 before—14
after G38 vs. 7 before—14 after G42.
Flexion = 4 before vs. 7 after G38 vs. 3 before—7 after G42.
Abduction = 4 before vs. 6 after G38 vs. 3 before—6 after
G42. External rotation = 2 before—5 after G38 vs. 2
before—4 after G42 (among groups after, p = 0.06). Internal
rotation = 4 before G38—5 after vs. 4 before—7 after G42.
Strength = 2 before—8 after G38 vs. 2 before—7 after G42.
-
Sebastià Forcada et al., 2014
Global score: 80 reverse vs. 56 partial.
Pain: 14 reverse vs. 9 partial. Activity:
17 reverse vs. 12 partial*.
Flexion = 120◦ reverse 80◦ partial*. Abduction = 113◦
reverse vs. 79◦ partial. External rotation = 5 reverse vs.
3 partial. Internal rotation= 3 reverse vs. 3 partial (p = 0.9).
UCLA score: 29 reverse vs. 21 partial.
DASH score: 17 reverse vs. 24 partial.
Boyer et al., 2017 Standard global score: 72 reverse vs.72 partial.
Flexion = 109◦ reverse vs. 99.5◦ partial. Abduction = 99◦
reverse vs. 90◦ partial. External rotation = 21◦ reverse vs.
28◦ partial.
QuickDASH: 36 reverse vs. 78 partial.
Alentorn-Geli et al., 2014
Standard global score: 35 before vs.
57 after, no improvement in internal
rotation. Greater difference before vs.
after in reverse arthroplasties (standard
global, front flexion and activity level)*.
- Score SF-36 (quality of life): No difference.
Jorge-Mora et al., 2018
Global score: 53 cemented vs.
60 non-cemented/63 union vs. 45
non-union (difference of 15 points
improvement).
Abduction = 92◦ cemented vs. 104◦ non-cemented/115◦
union vs. 68◦ non-union. Flexion = 92◦ cemented vs. 106◦
non-cemented/115◦ union vs. 69◦ non-union. Internal
rotation = 35◦ cemented vs. 36◦ non-cemented/38◦ union vs.
31◦ non-union. External rotation = 17◦ cemented vs. 23◦
non-cemented/28◦ union vs. 5◦ non-union.
-
Sebastià Forcada et al., 2017 Last standard global assessment:67 sequela vs. 78 fracture.
Strength = 2 sequela vs. 4 fracture. Flexion = 114◦ sequela
vs. 127◦ fracture. Abduction = 104◦ sequela vs. 120◦
fracture. External rotation = 4 sequela vs. 5 fracture
(p = 0.3). Internal rotation = 3 sequela vs. 3 fracture
(p = 0.7).
Last assessment: Pain VAS 8 sequela vs. 8 fracture (p = 0.9),
UCLA score: 26 sequela vs. fracture 29 fracture, QuickDASH
score: 21.5 sequela vs. 25 fracture. Satisfied patients: 93%.
Lopiz et al., 2016 Global score: Lower in the older group. No differences among groups at 24 months postintervention.
DASH score: 27 older group vs. 31 younger group (p = 0.1).
Problems reported in EQ-5D: anxiety (38% older vs. 12%
younger), pain/discomfort (23% vs. 12%), activity (38% vs.
0%), self-care (46% vs. 0%) and mobility (46% vs. 12%).
Health status and quality of life EQ-VAS: 63 younger vs.
74 older.
Bonilla et al., 2012 Global score: 32 before—57.5 after Deltavs. 31 before—60 after Comprehensive.
Flexion (before—after) = 95◦–130◦ Delta vs. 102◦–132◦
Comprehensive. Abduction (before—after) = 86◦–123◦
Delta vs. 98◦–118◦ Comprehensive. Internal rotation
(before—after) = 46%–44% Delta vs. 49%–61%
Comprehensive. External rotation (before—after) =
43%–64% Delta vs. 51%–61% Comprehensive.
-
Izquierdo-Fernández et al., 2017 - - ASES score: 75 vs. 63. Length of stay: 5 vs. 6 days (p = 0.3).
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Table 4. Cont.
Author, Year Constant–Murley Score Joint Assessment, by Constant–Murley Score Other Results
Cáceres-Sánchez et al., 2015 Global score: 23 before—67 at 12 months. External rotation = 26
◦ before—67◦ after. Flexion = 74◦
before—135◦ after
There are no metrics for fractures before the intervention.
EQ-VAS: 8 before vs. 2 at one-year follow-up. Satisfied
patients: 100%.
Martinez et al., 2012 Global score: 28 before—58 after.
Flexion = 40◦ before vs. 100◦ after. Abduction = 41◦ before
vs. 95◦ after. External rotation = 15◦ before vs. 35 after.
Internal rotation = 25◦ before vs. 60◦ after.
Estimation of proximity to a normal back: 13% before to 56%
after. Patient satisfaction: 86% satisfied or very satisfied.
Zafra et al., 2014 Global score: 23 before—65.5 after.
Flexion = 45◦ before vs. 117◦ after. Abduction = 39◦ before
vs. 96◦ after*. Internal rotation (no difference). External
rotation = 5◦ before vs. 15.5◦ after.
Cofield pain rating: 4.8 before vs. 1.77 after. Patient
perception of improvement after the intervention: 95%.
García-Fernandez et al., 2015 Patients with periprosthetic fracture satisfied at the end offollow-up: 61%.
Alcobía-Díaz et al., 2017 Standardized Constant score: 36 beforevs. 81 after.
Differences before vs. after: improved flexion (+15◦/5◦) and
abduction (+10◦/5◦), not in rotation (-2◦/0◦). Goutallier
classification: >2 grade.
Daily activity questionnaire: 20% limitation in shoulder
function with low-demand tasks, 51% limitation with
high-demand tasks. VAS pain = 3.5.
Torrens et al., 2016
Global score: 30 before—58 at one year.
Pain: 5 before vs. 10 at one-year
follow-up. Daily activities: 8 before vs.
14 at one-year follow-up.
Flexion = 4 before vs. 7 at one-year follow-up. Abduction =
4 before vs. 6 at one-year follow-up. External rotation = 3
before vs. 5 at one-year follow-up. Internal rotation = 4
before vs. 5 at one-year follow-up (p = 0.1). Strength = 2
before vs. 10 at one-year follow-up.
Patient perception of improvement: General = 80%,
(minimum 8 points), Strength = 62 % (minimum 11 points),
Anterior elevation = 73% (minimum 6 points), Lateral
rotation = 73% (minimum 2 points), Internal rotation = 38%
(minimum 2 points).
Torrens et al., 2017 Global score at 2-year follow-up: 54.Pain = 12. Daily activity = 15.
Flexion = 7, Abduction = 6, Lateral rotation = 5, Internal
rotation =5, Strength = 5.
C-reactive protein; increase after surgery, peak on the 2nd
day, recovery on the 14th.
Torrens et al., 2018
Global score at the end of follow-up: 61,
66 younger than 75 years vs. 57 older
than 75 years. Pain: 12.
Metrics at the end of follow-up. Flexion = 7, Abduction = 6
Lateral rotation = 5. Internal rotation = 5, Strength = 7. -
Delgado-Rodríguez et al., 2013
Flexion = 39◦ before vs. 84◦ after. External rotation = 13◦
before vs. 33◦ after. Internal rotation = 11◦ before vs. 31◦
after. Abduction = 32◦ before vs. 75◦ after.
QuickDASH score: 36% after. Pain VAS: 3.
Hernández-Elena et al., 2015 Global score: 63. Pain:14. Abduction = 104
◦. Flexion = 106◦. Internal rotation = 40◦.
External rotation = 46◦.
Villodre-Jiménez et al., 2016
Global score: 65. Best results in patients
with arm lengthening intervention
<20 mm.
Flexion = 124◦. External rotation = 13◦. Abduction = 95◦.
UCLA scale: 27 points. QuickDASH: 32. Best results in
QuickDASH in patients with arm lengthening intervention
<20 mm. Patients with moderate to severe pain: 20%. Patients
satisfied: 95%.
Andrés-Cano et al., 2014 Global score at the end of follow-up:44 points.
Active abduction = 50◦. Flexion = 70◦. External rotation:
50◦. Internal rotation: up to the lumbosacral joint.
QuickDASH: 24 points. Higher number of rehabilitation
sessions = QuickDASH. Less operating time = QuickDASH.
Pain EVA = 1 of 8.
G38: 38 mm glenosphere; G42: 42 mm glenosphere; -: no information available; UCLA: UCLA Shoulder rating Scale; DASH: Disabilities of the Arm Shoulder and Hand; SF-36: Short Form
36; ASES: American Shoulder and Elbow Surgeons; EQ-5D: Euro QoL 5D; VAS: Visual Analog Scale.
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4. Discussion
The results of the review show that shoulder arthroplasty in Spain can currently be considered
an effective and safe procedure, with functional recovery and pain reduction in patients operated on
for humeral fracture and rotator cuff arthropathy, fracture sequelae and malunion of the proximal
humerus, and degenerative diseases. These results are similar to those found in other countries,
including Norway, Germany, the Netherlands and the USA [9,15,49–51], with better results observed
with reverse-type arthroplasties than hemiarthroplasties.
Regarding the safety of shoulder arthroplasty, the overall complication rate in this procedure
appears to be centred around 15%, with the most commonly observed complications being instability,
periprosthetic fracture or infection [13,14]. The results obtained from this study show that the most
frequent complications in Spain were of the same profile as other countries, with similar rates also
reported [9,15,52–54]. In addition, increased safety has been observed in recent years worldwide as
reported by the Nordic or the Kaiser Permanente registers [15,55]. These improved results could be for
various reasons, with progress in prosthesis design being particularly relevant. The presence of reverse
prostheses should be noted as they have become one of the treatments of choice for pathologies like
proximal humeral fractures or rotator cuff arthropathy [56–59]. The results obtained when assessing
reverse prostheses suggest that, while their rate of complications might be slightly higher than those
observed in other contexts [9,15,52–54], their results could be better when compared to other types of
prostheses [32,33,36,48]. This facilitates the hypothesis that reduced incidence of the aforementioned
complications could be largely due to an increased use of these types of implants.
Currently, the evidence for implant survival in Spain at the population level is limited. However,
the results of the reviewed studies are similar to data from international registries, which estimate
an implant revision rate of approximately 90%–95% at 5 and 10 years [9,15,49,50,52]. In addition,
most of the prosthesis models identified in this review are commonly used internationally, and the
ODEP assessment of most of those included in the selected studies was acceptable [9,25]. Similar to
our results, the 10-year cumulative revision rate after primary reverse shoulder arthroplasty in the
Nordic countries was between 90% to 95% and the model most frequently used was Delta Xtend [55].
Moreover, the results from other European shoulder arthroplasty registers, including the National Joint
Registry (NJR) in the United Kingdom and the Dutch arthroplasty register (LROI) show that the results
in terms of survival rates might be similar across European countries and that the prosthesis models
most frequently used are usually the same [51,60]. However, considering the results for shoulder
arthroplasty effectiveness, in terms of functionality, pain and impact on the patient’s life, there is
some difference in calculating scores, which hinders synthesis [61,62]. Regardless of the calculation
differences, especially for the Constant–Murley test, improved scores after the intervention were
observed in the results of the studies reviewed. The results show that an improvement in pain could be
relevant, even at short-term follow-ups after arthroplasty, which is contrary to results suggested by a
previous study proposing that improvement in the short-term may not be as evident as in longer-term
follow-ups [63].
The authors accept that a significant limitation of the present study is the search strategy. Given
its focus on the Spanish population, extrapolating and generalizing its results to other populations is
challenging. However, we believe that delimiting the safety and effectiveness of shoulder arthroplasties
in a specific healthcare context may be useful in encouraging and improving results at all levels:
surgical, management, and patient. In addition, the results shown can be useful and relevant at
the international level when making comparisons and establishing common standards of reference.
It is also important to mention the limitation related to the inclusion criteria, given that patients
under 18 years old and patients with tumours were excluded. These criteria restrict the capacity to
extrapolate the results obtained to the whole population. Despite this limitation, the results found
could be applicable to most of patients eligible for a shoulder arthroplasty, and thus it is reasonable to
assume that they could be at least approaching the true results of these procedures in Spain. Another
limitation is related to the heterogeneity of the studies in terms of their design and presentation of
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results, which makes a meta-analysis impossible. However, the evidence presented was synthesized
as much as possible to be able to serve both as a reference in assessing the safety and effectiveness
of shoulder arthroplasty, and as a starting point for new studies on the subject. Lastly, these studies
were considered without stratifying by patient diagnosis or the severity of their symptoms. As such, it
is possible that some of the results described correspond to selected samples of patients with certain
diagnoses. Despite this, most of the studies focus on the two main reasons for intervention in shoulder
arthroplasty: fracture of the humerus and rotator cuff arthropathy, which is why we believe the results
shown can be widely generalized to the population susceptible to receiving a shoulder arthroplasty
and not only to those with one of the two diagnoses. However, further epidemiological research
stratified by these indications both in Spain and in other countries could be valuable to obtain a more
precise representation of the safety and effectiveness of shoulder arthroplasties at the population level.
5. Conclusions
In Spain, primary shoulder arthroplasties, for those who are able to receive them, are an effective
and safe procedure that allow functional recovery and pain reduction in patients with humeral fracture,
rotator cuff arthropathy, fracture sequelae and malunion of the proximal humerus, and degenerative
diseases. The prosthesis type with the best survival is the reverse prosthesis. Future longitudinal
population-based studies, particularly randomized controlled trials, as well as the establishment of a
shoulder arthroplasty registry could confirm these results and identify areas of improvement, including
the recommendation of specific types of prostheses or models with preferable results.
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Appendix A PubMed Filter
#1 shoulder[MeSH] OR shoulder[ti] OR humeral[ti] OR glenohumeral[ti] OR glenoid[ti]
#2 arthroplasty[MeSH] OR arthroplast*[ti] OR replacement[ti] OR “prosthesis implantation”
[MeSH] OR prosthes*[ti] OR implant* OR “prostheses and implants”[MeSH]
#3 Spain[tiab] OR Spanish[tiab] OR España[tiab] OR Espana[tiab] OR Espan*[tiab] OR
Andalusia*[tiab] OR Catalan*[tiab] OR Catalonian[tiab] OR Madrid[tiab] OR Madrilen*[tiab] OR
Madrileñ*[tiab] OR Valencian*[tiab] OR Galicia[tiab] OR Galego[tiab] OR Galleg*[tiab] OR Galaic[tiab]
OR “Castilla y Leon”[tiab] OR “Castilla and Leon”[tiab] OR Leones*[tiab] OR Basque[tiab] OR
basc*[tiab] OR “Castilla-La Mancha”[tiab] OR Canary[tiab] OR Canarian[tiab] OR Canari*[tiab]
OR Murcia[tiab] OR Murcian*[tiab] OR Aragon*[tiab] OR Extremadura[tiab] OR Extremeno[tiab]
OR Extremena[tiab] OR Extremeño[tiab] OR Extremeña[tiab] OR Balear[tiab] OR Asturias[tiab] OR
Asturian*[tiab] OR Navarra[tiab] OR Navarre[tiab] OR Cantabria[tiab] OR Cantabric*[tiab] OR “La
Rioja”[tiab] OR Riojan*[tiab]
#4 spain[MeSH] OR spain OR espagne OR espana OR spain[ad] OR espagne[ad] OR espana[ad] OR
osasunbidea[ad] OR osakidetza[ad] OR insalud[ad] OR sergas[ad] OR catalunya[ad] OR catalonia[ad]
OR catalogne[ad] OR cataluna[ad] OR catala[ad] OR barcelon[ad] OR barcelona[ad] OR barcelones[ad]
OR barceloneta[ad] OR barcelonia[ad] OR tarragona[ad] OR lleida[ad] OR lerida[ad] OR girona[ad]
OR gerona[ad] OR sabadell[ad] OR hospitalet[ad] OR l’hospitalet[ad] OR valencia[ad] OR castello[ad]
OR castellon[ad] OR alacant[ad] OR alicant[ad] OR alicante[ad] OR murcia[ad] OR murcian OR
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murciana[ad] OR murciano[ad] OR andaluci[ad] OR andalucia[ad] OR andaluciajunta[ad] OR
andalusi[ad] OR andalusia[ad] OR andalusian[ad] OR andaluz[ad] OR andaluza[ad] OR sevill[ad] OR
sevilla[ad] OR seville[ad] OR granada[ad] OR huelva[ad] OR almeria[ad] OR cadiz[ad] OR jaen[ad]
OR malaga[ad] OR extremadura[ad] OR caceres[ad] OR badajoz[ad] OR madrid[ad] OR galicia[ad]
OR gallego[ad] OR compostela[ad] OR vigo[ad] OR coruna[ad] OR ferrol[ad] OR orense[ad] OR
ourense[ad] OR pontevedra[ad] OR oviedo[ad] OR gijon[ad] OR asturia[ad] OR asturiano[ad] OR
asturias[ad] OR asturias[ad] OR cantabria[ad] OR cantabrico[ad] OR cantabro[ad] OR santander[ad] OR
vasco[ad] OR euskadi[ad] OR basque[ad] OR bilbao[ad] OR bilbo[ad] OR donosti[ad] OR donostia[ad]
OR vizcaya[ad] OR guipuzcoa[ad] OR gipuzkoa[ad] OR alava[ad] OR alaba[ad] OR vitoria[ad] OR
vitoria[ad] OR vitoria-gasteiz[ad] OR bizkaia[ad] OR navarra[ad] OR pamplona[ad] OR irunea[ad]
OR aragon[ad] OR aragones[ad] OR zaragoza[ad] OR teruel[ad] OR huesca[ad] OR mancha[ad] OR
“ciudad real”[ad] OR albacete[ad] OR cuenca[ad] OR balear[ad] OR baleares[ad] OR balearic[ad]
OR balears[ad] OR mallorca[ad] OR menorca[ad] OR ibiza[ad] OR eivissa[ad] OR palmas[ad] OR
lanzarote[ad] OR canaria[ad] OR canarian[ad] OR canarias[ad] OR canario[ad] OR tenerife[ad] OR
castilla[ad] OR salamanca[ad] OR zamora[ad] OR valladolid[ad] OR segovia[ad] OR soria[ad] OR
palencia[ad] OR avila[ad] OR burgos[ad] OR (leon[ad] NOT (france[ad] OR clermont[ad] OR rennes[ad]
OR lyon[ad] OR USA[ad] OR mexic[ad] OR mexica[ad])) OR (cordoba[ad] NOT (argentin[ad] OR
argentina[ad])) OR (toledo[ad] NOT (ohio[ad] OR us[ad] OR usa[ad] OR OH[ad])) OR (guadalajara[ad]
NOT (mexic[ad] OR mexica[ad] OR mexicali[ad] OR mexican[ad] OR mexicana[ad] OR mexicano[ad]
OR mexicanos[ad]))
#5 #1 AND #2 AND (#3 OR #4) Filters: Publication date from 2003/01/01
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